Page last updated: 2024-11-12

2-methylisoborneol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

2-methylisoborneol: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2-methylisoborneol : An bornane monoterpenoid comprising isoborneol carrying a 2-methyl substituent (the 1R,2R,4R-diastereomer). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID124525065
MeSH IDM0047137

Synonyms (1)

Synonym
2-methylisoborneol

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" formosum in Upper Paskeville Reservoir were found to be lethally toxic by intraperitoneal injection into mice (400 mg kg-1)."( Preliminary evidence of toxicity associated with the benthic cyanobacterium Phormidium in South Australia.
Baker, PD; Falconer, IR; Fergusson, KM; Humpage, AR; Lanthois, B; Nicholson, BC; Saint, CP; Steffensen, DA, 2001
)
0.31

Dosage Studied

ExcerptRelevanceReference
" The correlation between 2-MIB concentration and the FPA intensity of musty odor was compared with the dose-response curve generated in the laboratory by the FPA panelists."( Correlation of musty odor and 2-MIB in two drinking water treatment plants in South Taiwan.
Kao, HP; Lin, TF; Wong, JY, 2002
)
0.31
" For any given PAC dosage in a jar-test, removal efficiencies of 2-MIB and geosmin were increased in proportion to PAC dosage and were independent of their initial concentration in raw water for the tested PAC dosages."( Treatment of taste and odor material by oxidation and adsorption.
Baek, KH; Jung, SW; Yu, MJ, 2004
)
0.32
" The percent removal of trace odorants at any given time for a particular carbon dosage is irrelative to the initial concentration of the odor compounds."( Removal of earthy-musty odorants in drinking water by powdered activated carbon.
Liang, C; Sun, W; Wang, D; Yang, M; Zhang, S, 2005
)
0.33
" The removal percentage of trace MIB at any given time for a particular carbon dosage was irrelative to the initial concentration of MIB."( Comparative study on the removal technologies of 2-methylisoborneol (MIB) in drinking water.
Ge, XP; Liang, CZ; Sun, W; Wang, DS; Yang, M, 2006
)
0.33
" The results of the model applications showed that in particular the simplified equivalent background compound model is a useful tool to determine the PAC dosage required to reduce the T&O compounds below the threshold concentration."( Adsorption of geosmin and 2-methylisoborneol onto powdered activated carbon at non-equilibrium conditions: influence of NOM and process modelling.
Börnick, H; Engel, C; Worch, E; Zoschke, K, 2011
)
0.37
" The analysis evaluated the effect of PAC dosing in the liquid phase immediately before or after the coagulant addition."( Interference of iron as a coagulant on MIB removal by powdered activated carbon adsorption for low turbidity waters.
Margarida, M; Rosemeire, AL; Seckler, FF, 2013
)
0.39
" Two oxidant dosage strategies were compared in terms of the organic removal performance: a simultaneous dosing strategy (SiDS) and a successive dosing strategy (SuDS)."( Microcystis aeruginosa-laden water treatment using enhanced coagulation by persulfate/Fe(II), ozone and permanganate: Comparison of the simultaneous and successive oxidant dosing strategy.
Chen, W; Cheng, X; Li, G; Liang, H; Liu, B; Qu, F; Van der Bruggen, B; Wang, T; Yu, H, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (222)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (2.25)18.7374
1990's5 (2.25)18.2507
2000's81 (36.49)29.6817
2010's103 (46.40)24.3611
2020's28 (12.61)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews13 (5.86%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other209 (94.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]